Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression of miRNAs in ovarian cancer recurrence

ABSTRACT: Recurrence is the major cause of treatment failure in patients with ovarian cancer. The purpose of this study is to identify novel miRNAs contributing to ovarian cancer recurrence.

ORGANISM(S): Homo sapiens Primates

PROVIDER: GSE135469 | GEO | 2019/08/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression of miRNAs in ovarian cancer recurrence

Project description:Expression of miRNAs in ovarian cancer recurrence

| PRJNA558993 | ENA

EV-miRNAs as biomarkers of breast cancer recurrence

Project description:EV-miRNAs as biomarkers of breast cancer recurrence

| PRJNA992498 | ENA

EV-miRNAs as biomarkers of breast cancer recurrence

Project description:To evaluate the miRNAs expression related to breast cancer recurrence

2024-08-14 | GSE236845 | GEO

miRNAs in ovarian cancer: A systems approach

Project description:This SuperSeries is composed of the following subset Series: GSE23383: miRNAs in ovarian cancer: A systems approach (miRNA data) GSE23391: miRNAs in ovarian cancer: A systems approach (mRNA data) GSE27431: miRNAs in ovarian cancer: A systems approach (MAS5, plier, GCRMA) Refer to individual Series

2011-07-28 | E-GEOD-23392 | biostudies-arrayexpress

Analysis of extracellular vesicles (Evs) miRNAs in ovarian cancer

Project description:Analysis of extracellular vesicles (Evs) miRNAs in ovarian cancer

2025-04-30 | GSE278022 | GEO

Chemoproteomics-based discovery of novel biomarkers for high-grade serous ovarian cancer recurrence through a patient-derived xenograft strategy

Project description:High grade serous ovarian carcinoma (HGSC) is the most common and lethal subtype of gynecologic malignancy in women. The current standard of treatment combines cytoreductive surgery and chemotherapy. Despite the efficacy of initial treatment, most patients develop cancer recurrence, and 70% of patients die within 5-years of initial diagnosis. CA125 is the current FDA-approved biomarker used in the clinic to monitor response to treatment and recurrence. Although increasing levels of CA125 precede clinical symptoms of recurrence, often second-look surgeries often reveal microscopic and macroscopic tumors present during remission. Here, we describe a novel strategy for the discovery of serum biomarkers aimed at earlier detection of cancer recurrence. We combined HGSC patient-derived xenograft models, chemoproteomic enrichment of N-glycosylated peptides and systematic development of targeted proteomics assays for rapid biomarker identification and orthogonal verification. The verification of candidates in two independent, longitudinal serum cohorts from HGSC patients (n=96 serum samples) identified four novel biomarker candidates for earlier detection of HGSC recurrence.

2018-08-27 | MSV000082853 | MassIVE

microRNAs in ovarian cancer cell spheroids

Project description:Cancer stem cells can self-renew, proliferate into differentiated cells, or enter a quiescent state and are regarded to cause chemoresistance and recurrence. Fresh tumor cells from three ovarian cancer patients were cultured to isolated spheroid-forming cells (SFC; cancer stem-like cells). The miRNAs that exhibited significant differential expression between SFCs and adherent cells were identified using miRNAs microarrays.

2019-09-06 | GSE136925 | GEO

MicroRNA profiling of cisplatin-resistant and cisplatin-sensitive ovarian cancer cells

Project description:Platinum resistance is a major drawback in the treatment of ovarian cancer. Evidence suggests that microRNAs are key players in the initiation, progression, and drug resistance of cancer cells. However, the precise miRNAs dysregulated and contributing to platinum resistance in ovarian cancer cells have not been fully elucidated. Here, we conducted a miRNA expression profiling of cisplatin-sensitive (A2780) and cisplatin-resistant (CP20 and CIS) ovarian cancer cells to identify potential miRNAs involved in platinum resistance.

2020-11-20 | GSE161784 | GEO

Gene profile in ovarian cancer cell spheroids

2019-09-06 | GSE136924 | GEO

Repertoire of miRNAs in epithelial ovarian cancer determined by next generation sequencing of small RNA cDNA libraries

Project description:Background: MicroRNAs (miRNAs) are small regulatory RNAs that are implicated in cancer pathogenesis and have recently shown promise as blood-based biomarkers for cancer detection. Epithelial ovarian cancer is a deadly disease for which improved outcomes could be achieved by successful early detection and enhanced understanding of molecular pathogenesis that leads to improved therapies. A critical step toward these goals is to establish a comprehensive view of miRNAs expressed in epithelial ovarian cancer tissues as well as in normal ovarian surface epithelial cells. Methodology: We used massively parallel pyrosequencing (i.e., M-bM-^@M-^\454 sequencingM-bM-^@M-^]) to discover and characterize novel and known miRNAs expressed in primary cultures of normal human ovarian surface epithelium (HOSE) and in tissue from three of the most common histotypes of ovarian cancer. Deep sequencing of small RNA cDNA libraries derived from normal HOSE and ovarian cancer samples yielded a total of 738,710 high-quality sequence reads, generating comprehensive digital profiles of miRNA expression. Expression profiles for 498 previously annotated miRNAs were delineated and we discovered six novel miRNAs and 39 candidate miRNAs. A set of 124 miRNAs was differentially expressed in normal versus cancer samples and 38 miRNAs were differentially expressed across histologic subtypes of ovarian cancer. Taqman qRT-PCR performed on a subset of miRNAs confirmed results of the sequencing-based study.

2009-03-12 | E-GEOD-15190 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data